Lung cancer in never smokers: The 60x risk factor you might be missing
A specific EGFR variant significantly increases lung cancer risk in individuals who have never smoked, challenging traditional views on lung cancer etiology. This genetic predisposition highlights a critical, often overlooked, pathway to disease development.
PD-L1 isn't just a biomarker for HNSCC, it's a treatment guide
PD-L1 expression guides immunotherapy selection in recurrent and metastatic head and neck squamous cell carcinoma, with varying efficacy across patient subgroups.
Ovarian cancer: Early detection isn't the answer we thought
Ovarian cancer continues to be diagnosed at advanced stages, despite decades of research into effective screening methods. The disease's insidious nature and lack of reliable early detection tools contribute to poor outcomes.
RET-altered thyroid cancer: how selective inhibitors changed advanced disease
HPV-positive OPSCC: Are we overtreating excellent prognoses?
Radioactive iodine: Which low-risk thyroid cancer patients can safely skip it?
PD-L1 as a compass for immunotherapy in head and neck cancer
Low-risk thyroid cancer: Time to rethink radioactive iodine?
PPIs and cancer: Is CYP2C19 a friend or foe?
Pruritus in primary biliary cholangitis: the symptom that drives quality of life
Pruritus significantly impacts quality of life in primary biliary cholangitis, driving patient-reported outcomes and necessitating targeted management strategies.
Coffee may cut liver disease risk, related mortality
Regular coffee consumption correlates with a reduced risk of chronic liver disease and associated mortality, according to UK Biobank data.
Seladelpar and elafibranor: second-line options for PBC
For patients with primary biliary cholangitis (PBC) who do not respond adequately to ursodeoxycholic acid, seladelpar and elafibranor offer new therapeutic avenues.
MASH: Why diabetes management now demands a liver-first approach?
TNF emerges as a key node in autoimmune hepatitis, trial shows
Cholangiocarcinoma Surveillance: What Interval, What Modality in PSC?
ACLF: Why G-CSF works for some, but fails others
Why primary sclerosing cholangitis remains a therapeutic graveyard
Seladelpar and Elafibranor: The Second-Line Options for PBC After Ursodeoxycholic Acid Fails
Rethinking xylitol: Is this 'healthy' sugar substitute a cardiac threat?
Xylitol, a common sugar alcohol, has been linked to an elevated risk for major adverse cardiovascular events, raising concerns about its widespread use.
Eplontersen for ATTR-CM: Why a promising therapy fell short
Eplontersen, when added to standard care, did not demonstrate additional cardiovascular benefit for patients with ATTR-CM. The therapy's impact on cardiac outcomes remains unconfirmed.
Milvexian fails to cut ischemic risk in recent ACS, raising questions for FXIa inhibitors
Milvexian did not reduce ischemic events in patients with recent acute coronary syndrome, despite its mechanism as a factor XIa inhibitor.
Endocarditis: Why fixed-dose ampicillin often misses the mark
Biomarkers predict early rhythm control benefit in AFib
Beyond diagnosis: ECG waveforms predict MI-E treatment response
DOACs for AFib: Are intermediate-risk patients getting the protection they need?
Hypertension: Do shorter wall squats work as well for older women?
LAA occlusion: Less bleeding, but is stroke risk truly equal?
Bariatric surgery's decline: Is it more than GLP-1s?
Bariatric surgery rates saw a decline before the COVID-19 pandemic, a trend that predates the widespread adoption of GLP-1 receptor agonists for weight management.
Automated insulin delivery: Why pregnancy makes glucose control harder
Automated insulin delivery systems offer improved glucose control, but pregnancy and menstrual cycle variations present unique challenges for optimal management.
Amylin analogues: The missing piece in cardiometabolic care?
Amylin analogues are emerging as a potential new class of therapy for cardiometabolic disease, building on established physiological roles in glucose homeostasis and satiety.
Metformin for prediabetes: Is early use the new standard?
Predictive CGM: Stop chasing nocturnal lows, prevent them
Type 2 diabetes: What if insulin only needed to be weekly?
GLP-1 'super responders' aren't who you think they are
GLP-1s: Why higher BMI doesn't protect bones in diabetes
Rethinking GLP-1s: Beyond diabetes, a new cardiometabolic role
Vestibular Migraine vs. Meniere Disease: Separating Overlapping Diagnoses
Differentiating vestibular migraine from Meniere disease remains a clinical challenge, but emerging biomarkers and refined diagnostic criteria offer clearer distinctions.
Alzheimer's blood tests: Why are unverified claims spreading so fast?
Unverified claims about a new Alzheimer's blood test are circulating online, creating confusion for patients and clinicians alike. These claims often overstate the test's diagnostic capabilities and clinical utility.
Do CGRP Monoclonal Antibodies Offer Relief for Vestibular Migraine Vertigo?
CGRP monoclonal antibodies, established for migraine prophylaxis, are being explored for their potential to reduce vertigo attacks in vestibular migraine, a condition often challenging to manage.
Why long COVID research still struggles with a case definition
Hyperactivity and ID: It's not just genetics, it's O-GlcNAc dyshomeostasis
Why HINTS examination outperforms imaging for acute vertigo
Bilateral Focused Ultrasound: A New Path for Parkinson's Motor Control?
Dual-target gene therapy: Can it free Parkinson's patients from levodopa dependence?
Noninvasive Ventilation: A Shift in End-of-Life Care for ALS?
The most resistant cancer is finally responding, and the pipeline is accelerating
Lecanemab and donanemab are approved. The harder question is who gets them and how
Label expansion triples the eligible population and the infrastructure race begins
From 1 approval to 15: how the ADC platform reshaped every solid tumor type
Four bispecific antibodies, two CAR-T therapies, and a treatment landscape that moves monthly
Polycythemia VeraHaematocrit targets: Is 45% still the right threshold for phlebotomy?
Get the full storyWhy molecular response in polycythemia vera remains an elusive endpoint
Get the full storyPNH: Beyond Eculizumab, How Proximal Inhibition Reshaped Treatment Goals
Get the full storyWhen complement inhibitors fail: Recognizing breakthrough haemolysis
Get the full storyOral factor B inhibition: a new path for PNH management?
Get the full storyMyelofibrosis: Why transplant timing dictates survival, not just symptoms
Get the full storyChoosing a JAK Inhibitor in Myelofibrosis: Beyond Ruxolitinib
Get the full storyMomelotinib and anaemia in myelofibrosis: a new calculus for treatment?
Get the full storyGene therapy for thalassemia: Approval is one hurdle, access is the next
Get the full storyIron chelation in gene therapy: When to stop, and how to monitor
Get the full story
Idiopathic Pulmonary FibrosisUndiagnosed TB deaths in England highlight diagnostic failures
AdvertisementAdvertisementAdvertisement
• Sep 28 – Oct 2UEG Week 2026 • Barcelona, ES 
• Oct 17 – 20Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA 
• Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27ACR 2026 • Orlando, US 
• Nov 6 – 11AHA 2026 • Chicago, US • Nov 6 – 9ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12EASD 2026 • Milan, IT • Sep 28 – Oct 2UEG Week 2026 • Barcelona, ES • Oct 17 – 20Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA • Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27ACR 2026 • Orlando, US • Nov 6 – 11AHA 2026 • Chicago, US • Nov 6 – 9ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12
Advertisement
BarcelonaSep 5 – 9 2026
Severe asthma: Why targeted therapies miss some Type 2 patients
Emerging clinical insights suggest the distal airways play a more central role in Type 2 severe asthma pathophysiology than previously understood.
Respiratory care: Why neurology's long-acting therapies could be key
Insights from multiple sclerosis treatment paradigms offer a framework for developing ultra-long-acting therapies in respiratory care, addressing adherence and disease progression.
Rethink PDE inhibition in COPD: Not all isoforms are equal
Phosphodiesterase (PDE) inhibitors offer therapeutic potential in COPD, but adverse effects, particularly nausea with PDE4 inhibitors and cardiovascular risks with chronic PDE3 inhibition, limit their broader application.
RSV and COVID-19 vaccines: Why are we still underestimating their impact?
Vaccination against RSV and COVID-19 offers a critical strategy for mitigating the burden of respiratory diseases, particularly in vulnerable populations.
PH-ILD: Why current vasodilators fall short, and what's next
An inhaled sGC activator is under investigation for pulmonary hypertension associated with interstitial lung disease, a condition with significant unmet need.
Alpha-1 Antitrypsin Deficiency: Why fragmented care costs lives
Alpha-1 antitrypsin deficiency presents as both a respiratory and hepatic disease, often leading to diagnostic delays and suboptimal management due to fragmented care.
Air pollution: Why policies fail, and patients pay the price
Despite clear evidence linking air pollution to adverse health outcomes, effective implementation of protective policies remains a significant hurdle.
Beyond diagnosis: ECG waveforms predict MI-E treatment response
Electrocardiogram waveforms offer insights into myocardial infarction with epicardial coronary artery disease (MI-E) efficacy, providing a non-invasive window into myocardial health.
COPD exercise limits: Is your oxygen therapy doing enough?
High-flow humidified oxygen improved exercise endurance and reduced dyspnea in patients with advanced COPD compared to conventional low-flow oxygen.
Beyond rescue inhalers: What really keeps COPD patients out of hospital?
Preventing hospital admissions for COPD requires a comprehensive approach, moving beyond acute symptom management to address the underlying disease progression and comorbidities.
IPF: Why new therapies are still missing the mark
The TETON Phase 3 clinical program provides new insights into the management of idiopathic pulmonary fibrosis, highlighting both progress and persistent challenges.
COPD: Why focusing only on exacerbations misses the bigger picture?
COPD management extends beyond preventing exacerbations, encompassing symptom burden, exercise capacity, and quality of life for a holistic patient approach.
Bronchiectasis: Why symptom control isn't enough anymore
Bronchiectasis management is evolving beyond symptomatic relief, with a focus on neutrophil-driven inflammation as a target for disease modification.
COPD exacerbations: Why RSV's hidden role demands a new vaccine strategy
RSV infection significantly destabilizes COPD, driving exacerbations and hospitalizations. The adjuvanted RSV vaccine offers a new tool to mitigate this risk.
Pulmonary fibrosis: Why early diagnosis remains a clinical enigma
Pulmonary fibrosis presents significant diagnostic and treatment challenges, often leading to delayed intervention and poorer outcomes for patients.
Beyond the numbers: What your PFT results are really telling you
Pulmonary function tests require an approach beyond simple normal/abnormal classifications, integrating clinical context and patient demographics for accurate diagnosis.
Sleep Apnea: Why AHI Misses What Matters Most
Traditional AHI metrics often miss the full impact of sleep apnea; hypoxic burden and specific phenotyping offer a clearer picture of patient risk and device efficacy.
COPD: Why one moderate exacerbation changes everything
One moderate COPD exacerbation should prompt clinicians to consider stepping up from dual bronchodilator therapy to a single-inhaler triple therapy.
NIV adherence: Why patient engagement is the real determinant of outcomes
Engaging patients actively in their non-invasive ventilation (NIV) therapy improves adherence and clinical outcomes. Education, shared decision-making, and tailored support are critical for success.
Severe asthma: Why biologics aren't delivering remission
Severe asthma remission is rare, even with biologic treatments, according to a European registry study highlighting persistent disease burden.
Why targeting IL-33 could change how we manage COPD
Interleukin-33 plays a complex role in COPD pathogenesis, driving both inflammation and mucus production, which contributes to exacerbation risk.
Airway mucus: Is it a symptom or the disease driver in lung conditions?
Airway mucus obstruction is a central feature of many chronic lung diseases, contributing to inflammation, infection, and progressive lung damage.
Severe asthma, COPD: Why symptom control isn't enough
Managing severe asthma and COPD requires timely intervention, moving beyond symptomatic relief to address underlying inflammation and prevent exacerbations.
Chronic respiratory disease: Why diagnosis often comes too late
Understanding the patient journey for chronic respiratory diseases in resource-limited settings reveals significant diagnostic and treatment delays, impacting long-term outcomes.
Epithelial health: more than a symptom of chronic inflammation?
Maintaining epithelial barrier integrity is emerging as a critical factor in achieving disease remission, moving beyond traditional symptom management in chronic inflammatory conditions.
Asthma care: Your patients need more than symptom relief
Current asthma management focuses on symptom control and exacerbation reduction, but patient-reported outcomes highlight persistent unmet needs.
Obesity hypoventilation: CPAP vs. NIV, the economic tension
Obesity hypoventilation syndrome (OHS) can be managed with either CPAP or NIV, with device choice impacting economics and operations.
Pneumococcal disease: Your patients need updated protection now
Pneumococcal disease remains a significant global health burden, with new GBD 2023 data highlighting persistent mortality in vulnerable populations.
OSA: Why AHI alone isn't predicting your patients' heart risk
The apnea-hypopnea index (AHI) remains the standard for obstructive sleep apnea diagnosis, but its limitations in predicting cardiovascular outcomes are clear.
High-flow oxygen: The unexpected boost for COPD endurance?
High-flow humidified oxygen improved exercise endurance and reduced dyspnea in patients with advanced COPD compared to conventional low-flow oxygen.
Ventilation: Why static guidelines fail dynamic patients
Continuous-improvement ventilation relies on real-world data to refine protocols and enhance patient outcomes, moving beyond static guidelines.
Chronic lung disease: Why early diagnosis still isn't enough
Managing chronic lung diseases presents complex challenges, from accurate diagnosis to optimising long-term treatment strategies and addressing patient adherence.
NTM lung disease: Why are we still missing it?
Non-tuberculous mycobacterial lung disease presents significant diagnostic and therapeutic challenges, often leading to delayed intervention and suboptimal patient outcomes.
OPEP therapy: Is your current mucus clearance falling short?
Oscillating positive expiratory pressure (OPEP) therapy offers a non-pharmacological approach to mucus clearance across various respiratory conditions.
Rhinitis isn't just a nuisance: It's a key to managing asthma and COPD
Chronic inflammatory diseases of the upper and lower airways are often comorbid, sharing underlying pathophysiological mechanisms. Integrated management is essential for optimal patient outcomes.
COPD: Why dual bronchodilation still isn't working for some patients
Dual bronchodilation remains a cornerstone in COPD management, focusing on symptom control and exacerbation reduction.
Why treating asthma and CRSwNP separately may fail your patients
Anosmia, or loss of smell, may serve as a crucial indicator of shared inflammatory pathways between asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), suggesting a unified airway disease. Its presence signals a systemic type 2 inflammatory burden that impacts treatment decisions and patient quality of life.
IPF, PPF: Why patient and clinician views on disease impact diverge
Idiopathic pulmonary fibrosis and progressive pulmonary fibrosis present unique challenges, with patient and pulmonologist perspectives often misaligned on disease impact and management.
Asthma, COPD: Why the 'right' drug often fails in the 'wrong' device
Matching the right inhaler device to a patient's needs remains a persistent challenge in respiratory care, despite a wide array of available options.
Rethinking PCV: Not all conjugate vaccines are equal for chronic lung disease
Real-world evidence on pneumococcal conjugate vaccines (PCVs) highlights differential effectiveness in adults with chronic lung disease.
COPD & asthma: Why symptom control isn't enough anymore
Current management of COPD and asthma focuses on symptom control, but emerging strategies aim to alter disease progression itself.
Pulmonary Hypertension: Why are we still going systemic?
Inhaled therapies are increasingly central to managing pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, offering targeted delivery and reduced systemic side effects.
Stop missing ILD: AI reveals what the eye can't see
Integrating artificial intelligence with clinical expertise can accelerate the identification of interstitial lung disease, potentially improving patient outcomes.
Bronchoscopy training: Why 'hundreds of procedures' may no longer be enough
AI integration into flexible bronchoscopy training aims to improve procedural proficiency and diagnostic accuracy for respiratory specialists.
Personalized COPD care: Is your current approach missing the mark?
New approaches to chronic obstructive pulmonary disease (COPD) management focus on phenotype-guided therapies and early intervention strategies.
Pulmonary hypertension: Are we missing a key driver of vascular remodeling?
The insulin-like growth factor (IGF) family contributes to vascular remodeling and endothelial dysfunction in PAH, suggesting potential as diagnostic biomarkers and therapeutic targets.
Pulmonary fibrosis: Is inflammation friend or foe?
Fibrotic interstitial lung diseases involve intertwined inflammation and fibrosis, with varying contributions that demand personalized treatment approaches.
Eosinophil depletion: Why 'good enough' isn't enough anymore
Near-complete depletion of eosinophils is critical for optimal outcomes in eosinophil-driven diseases, moving beyond simple reduction to target the underlying pathogenic mechanism.
Rethinking asthma control: Why 'stable' isn't always enough
Achieving rapid and sustained control of asthma symptoms is critical for preventing exacerbations and improving long-term patient outcomes.
Asthma: Why are we still guessing when omics can personalize care?
New reviews highlight how omics technologies and artificial intelligence are transforming asthma diagnosis, prognosis, and treatment decisions, moving beyond empirical approaches.
Severe asthma, CRSwNP: Why targeting TSLP upstream changes everything
Thymic stromal lymphopoietin (TSLP) inhibition offers a novel strategy for epithelial-driven inflammatory diseases like severe asthma and chronic rhinosinusitis with nasal polyps.
Pulmonary alveolar proteinosis: Your patients deserve better
Pulmonary alveolar proteinosis (PAP) management across Europe faces significant disparities, driven by varied access to diagnostic tools and treatment modalities. A unified approach is critical for improving patient outcomes.
Alpha-1 Antitrypsin Deficiency: Beyond augmentation, a new path
Advancements in Alpha-1 Antitrypsin Deficiency (AATD) therapies focus on restoring functional AAT levels and achieving clinically meaningful endpoints beyond simple protein augmentation.
Pulmonary Hypertension: Your objective measures aren't telling the whole story
Patient-reported outcomes are essential for understanding the true burden of pulmonary arterial hypertension and guiding treatment decisions.
Rethinking COPD: Dupilumab shows type 2 inflammation matters
Dupilumab has demonstrated efficacy in both asthma and COPD, offering a new therapeutic avenue for patients with underlying type 2 inflammation.
COPD: Why are we still missing early diagnoses?
Chronic obstructive pulmonary disease often goes undiagnosed until advanced stages, delaying interventions that could improve patient outcomes. Identifying at-risk individuals earlier is critical for effective management.
Respiratory inhalers: The hidden climate cost of patient care?
Addressing the environmental impact of respiratory care, particularly inhaler use, is becoming a critical consideration for clinical practice.
Pulmonary alveolar proteinosis: It's not surfactant overproduction
Autoimmune pulmonary alveolar proteinosis (aPAP) results from impaired GM-CSF signaling, leading to surfactant accumulation. Management focuses on whole lung lavage, but targeted therapies are emerging.
Why CPAP success isn't about the device, but the patient experience
Optimising CPAP therapy requires a shift from device-centric views to patient-centred care, addressing comfort, education, and ongoing support.
Long-term oxygen therapy: Are we missing the patient experience?
A new questionnaire, QuOTE, offers a simple, patient-reported method to evaluate the impact of long-term oxygen therapy on daily life. This tool provides a direct measure of patient experience, which has been historically difficult to quantify.
Central sleep apnea: Why aren't we using ASV more?
Auto-servo ventilation (ASV) therapy is a guideline-recommended treatment for central sleep apnea (CSA), but its adoption in clinical practice remains inconsistent. Understanding ASV's mechanism and patient selection is important for optimal outcomes.
COPD: Early aggressive therapy isn't just for lungs
Delayed optimisation of COPD management leads to significant adverse cardiopulmonary outcomes, underscoring the need for earlier, aggressive therapeutic strategies.
Severe asthma: Why targeted therapies miss some Type 2 patients
Emerging clinical insights suggest the distal airways play a more central role in Type 2 severe asthma pathophysiology than previously understood.
Respiratory care: Why neurology's long-acting therapies could be key
Insights from multiple sclerosis treatment paradigms offer a framework for developing ultra-long-acting therapies in respiratory care, addressing adherence and disease progression.
Rethink PDE inhibition in COPD: Not all isoforms are equal
Phosphodiesterase (PDE) inhibitors offer therapeutic potential in COPD, but adverse effects, particularly nausea with PDE4 inhibitors and cardiovascular risks with chronic PDE3 inhibition, limit their broader application.
RSV and COVID-19 vaccines: Why are we still underestimating their impact?
Vaccination against RSV and COVID-19 offers a critical strategy for mitigating the burden of respiratory diseases, particularly in vulnerable populations.
PH-ILD: Why current vasodilators fall short, and what's next
An inhaled sGC activator is under investigation for pulmonary hypertension associated with interstitial lung disease, a condition with significant unmet need.
Alpha-1 Antitrypsin Deficiency: Why fragmented care costs lives
Alpha-1 antitrypsin deficiency presents as both a respiratory and hepatic disease, often leading to diagnostic delays and suboptimal management due to fragmented care.
Air pollution: Why policies fail, and patients pay the price
Despite clear evidence linking air pollution to adverse health outcomes, effective implementation of protective policies remains a significant hurdle.
Beyond diagnosis: ECG waveforms predict MI-E treatment response
Electrocardiogram waveforms offer insights into myocardial infarction with epicardial coronary artery disease (MI-E) efficacy, providing a non-invasive window into myocardial health.
COPD exercise limits: Is your oxygen therapy doing enough?
High-flow humidified oxygen improved exercise endurance and reduced dyspnea in patients with advanced COPD compared to conventional low-flow oxygen.
Beyond rescue inhalers: What really keeps COPD patients out of hospital?
Preventing hospital admissions for COPD requires a comprehensive approach, moving beyond acute symptom management to address the underlying disease progression and comorbidities.
IPF: Why new therapies are still missing the mark
The TETON Phase 3 clinical program provides new insights into the management of idiopathic pulmonary fibrosis, highlighting both progress and persistent challenges.
COPD: Why focusing only on exacerbations misses the bigger picture?
COPD management extends beyond preventing exacerbations, encompassing symptom burden, exercise capacity, and quality of life for a holistic patient approach.
Bronchiectasis: Why symptom control isn't enough anymore
Bronchiectasis management is evolving beyond symptomatic relief, with a focus on neutrophil-driven inflammation as a target for disease modification.
COPD exacerbations: Why RSV's hidden role demands a new vaccine strategy
RSV infection significantly destabilizes COPD, driving exacerbations and hospitalizations. The adjuvanted RSV vaccine offers a new tool to mitigate this risk.
Pulmonary fibrosis: Why early diagnosis remains a clinical enigma
Pulmonary fibrosis presents significant diagnostic and treatment challenges, often leading to delayed intervention and poorer outcomes for patients.
Beyond the numbers: What your PFT results are really telling you
Pulmonary function tests require an approach beyond simple normal/abnormal classifications, integrating clinical context and patient demographics for accurate diagnosis.
Sleep Apnea: Why AHI Misses What Matters Most
Traditional AHI metrics often miss the full impact of sleep apnea; hypoxic burden and specific phenotyping offer a clearer picture of patient risk and device efficacy.
COPD: Why one moderate exacerbation changes everything
One moderate COPD exacerbation should prompt clinicians to consider stepping up from dual bronchodilator therapy to a single-inhaler triple therapy.
NIV adherence: Why patient engagement is the real determinant of outcomes
Engaging patients actively in their non-invasive ventilation (NIV) therapy improves adherence and clinical outcomes. Education, shared decision-making, and tailored support are critical for success.
Severe asthma: Why biologics aren't delivering remission
Severe asthma remission is rare, even with biologic treatments, according to a European registry study highlighting persistent disease burden.
Why targeting IL-33 could change how we manage COPD
Interleukin-33 plays a complex role in COPD pathogenesis, driving both inflammation and mucus production, which contributes to exacerbation risk.
Airway mucus: Is it a symptom or the disease driver in lung conditions?
Airway mucus obstruction is a central feature of many chronic lung diseases, contributing to inflammation, infection, and progressive lung damage.
Severe asthma, COPD: Why symptom control isn't enough
Managing severe asthma and COPD requires timely intervention, moving beyond symptomatic relief to address underlying inflammation and prevent exacerbations.
Chronic respiratory disease: Why diagnosis often comes too late
Understanding the patient journey for chronic respiratory diseases in resource-limited settings reveals significant diagnostic and treatment delays, impacting long-term outcomes.
Epithelial health: more than a symptom of chronic inflammation?
Maintaining epithelial barrier integrity is emerging as a critical factor in achieving disease remission, moving beyond traditional symptom management in chronic inflammatory conditions.
Asthma care: Your patients need more than symptom relief
Current asthma management focuses on symptom control and exacerbation reduction, but patient-reported outcomes highlight persistent unmet needs.
Obesity hypoventilation: CPAP vs. NIV, the economic tension
Obesity hypoventilation syndrome (OHS) can be managed with either CPAP or NIV, with device choice impacting economics and operations.
Pneumococcal disease: Your patients need updated protection now
Pneumococcal disease remains a significant global health burden, with new GBD 2023 data highlighting persistent mortality in vulnerable populations.
OSA: Why AHI alone isn't predicting your patients' heart risk
The apnea-hypopnea index (AHI) remains the standard for obstructive sleep apnea diagnosis, but its limitations in predicting cardiovascular outcomes are clear.
High-flow oxygen: The unexpected boost for COPD endurance?
High-flow humidified oxygen improved exercise endurance and reduced dyspnea in patients with advanced COPD compared to conventional low-flow oxygen.
Ventilation: Why static guidelines fail dynamic patients
Continuous-improvement ventilation relies on real-world data to refine protocols and enhance patient outcomes, moving beyond static guidelines.
Chronic lung disease: Why early diagnosis still isn't enough
Managing chronic lung diseases presents complex challenges, from accurate diagnosis to optimising long-term treatment strategies and addressing patient adherence.
NTM lung disease: Why are we still missing it?
Non-tuberculous mycobacterial lung disease presents significant diagnostic and therapeutic challenges, often leading to delayed intervention and suboptimal patient outcomes.
OPEP therapy: Is your current mucus clearance falling short?
Oscillating positive expiratory pressure (OPEP) therapy offers a non-pharmacological approach to mucus clearance across various respiratory conditions.
Rhinitis isn't just a nuisance: It's a key to managing asthma and COPD
Chronic inflammatory diseases of the upper and lower airways are often comorbid, sharing underlying pathophysiological mechanisms. Integrated management is essential for optimal patient outcomes.
COPD: Why dual bronchodilation still isn't working for some patients
Dual bronchodilation remains a cornerstone in COPD management, focusing on symptom control and exacerbation reduction.
Why treating asthma and CRSwNP separately may fail your patients
Anosmia, or loss of smell, may serve as a crucial indicator of shared inflammatory pathways between asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), suggesting a unified airway disease. Its presence signals a systemic type 2 inflammatory burden that impacts treatment decisions and patient quality of life.
IPF, PPF: Why patient and clinician views on disease impact diverge
Idiopathic pulmonary fibrosis and progressive pulmonary fibrosis present unique challenges, with patient and pulmonologist perspectives often misaligned on disease impact and management.
Asthma, COPD: Why the 'right' drug often fails in the 'wrong' device
Matching the right inhaler device to a patient's needs remains a persistent challenge in respiratory care, despite a wide array of available options.
Rethinking PCV: Not all conjugate vaccines are equal for chronic lung disease
Real-world evidence on pneumococcal conjugate vaccines (PCVs) highlights differential effectiveness in adults with chronic lung disease.
COPD & asthma: Why symptom control isn't enough anymore
Current management of COPD and asthma focuses on symptom control, but emerging strategies aim to alter disease progression itself.
Pulmonary Hypertension: Why are we still going systemic?
Inhaled therapies are increasingly central to managing pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, offering targeted delivery and reduced systemic side effects.
Stop missing ILD: AI reveals what the eye can't see
Integrating artificial intelligence with clinical expertise can accelerate the identification of interstitial lung disease, potentially improving patient outcomes.
Bronchoscopy training: Why 'hundreds of procedures' may no longer be enough
AI integration into flexible bronchoscopy training aims to improve procedural proficiency and diagnostic accuracy for respiratory specialists.
Personalized COPD care: Is your current approach missing the mark?
New approaches to chronic obstructive pulmonary disease (COPD) management focus on phenotype-guided therapies and early intervention strategies.
Pulmonary hypertension: Are we missing a key driver of vascular remodeling?
The insulin-like growth factor (IGF) family contributes to vascular remodeling and endothelial dysfunction in PAH, suggesting potential as diagnostic biomarkers and therapeutic targets.
Pulmonary fibrosis: Is inflammation friend or foe?
Fibrotic interstitial lung diseases involve intertwined inflammation and fibrosis, with varying contributions that demand personalized treatment approaches.
Eosinophil depletion: Why 'good enough' isn't enough anymore
Near-complete depletion of eosinophils is critical for optimal outcomes in eosinophil-driven diseases, moving beyond simple reduction to target the underlying pathogenic mechanism.
Rethinking asthma control: Why 'stable' isn't always enough
Achieving rapid and sustained control of asthma symptoms is critical for preventing exacerbations and improving long-term patient outcomes.
Asthma: Why are we still guessing when omics can personalize care?
New reviews highlight how omics technologies and artificial intelligence are transforming asthma diagnosis, prognosis, and treatment decisions, moving beyond empirical approaches.
Severe asthma, CRSwNP: Why targeting TSLP upstream changes everything
Thymic stromal lymphopoietin (TSLP) inhibition offers a novel strategy for epithelial-driven inflammatory diseases like severe asthma and chronic rhinosinusitis with nasal polyps.
Pulmonary alveolar proteinosis: Your patients deserve better
Pulmonary alveolar proteinosis (PAP) management across Europe faces significant disparities, driven by varied access to diagnostic tools and treatment modalities. A unified approach is critical for improving patient outcomes.
Alpha-1 Antitrypsin Deficiency: Beyond augmentation, a new path
Advancements in Alpha-1 Antitrypsin Deficiency (AATD) therapies focus on restoring functional AAT levels and achieving clinically meaningful endpoints beyond simple protein augmentation.
Pulmonary Hypertension: Your objective measures aren't telling the whole story
Patient-reported outcomes are essential for understanding the true burden of pulmonary arterial hypertension and guiding treatment decisions.
Rethinking COPD: Dupilumab shows type 2 inflammation matters
Dupilumab has demonstrated efficacy in both asthma and COPD, offering a new therapeutic avenue for patients with underlying type 2 inflammation.
COPD: Why are we still missing early diagnoses?
Chronic obstructive pulmonary disease often goes undiagnosed until advanced stages, delaying interventions that could improve patient outcomes. Identifying at-risk individuals earlier is critical for effective management.
Respiratory inhalers: The hidden climate cost of patient care?
Addressing the environmental impact of respiratory care, particularly inhaler use, is becoming a critical consideration for clinical practice.
Pulmonary alveolar proteinosis: It's not surfactant overproduction
Autoimmune pulmonary alveolar proteinosis (aPAP) results from impaired GM-CSF signaling, leading to surfactant accumulation. Management focuses on whole lung lavage, but targeted therapies are emerging.
Why CPAP success isn't about the device, but the patient experience
Optimising CPAP therapy requires a shift from device-centric views to patient-centred care, addressing comfort, education, and ongoing support.
Long-term oxygen therapy: Are we missing the patient experience?
A new questionnaire, QuOTE, offers a simple, patient-reported method to evaluate the impact of long-term oxygen therapy on daily life. This tool provides a direct measure of patient experience, which has been historically difficult to quantify.
Central sleep apnea: Why aren't we using ASV more?
Auto-servo ventilation (ASV) therapy is a guideline-recommended treatment for central sleep apnea (CSA), but its adoption in clinical practice remains inconsistent. Understanding ASV's mechanism and patient selection is important for optimal outcomes.
COPD: Early aggressive therapy isn't just for lungs
Delayed optimisation of COPD management leads to significant adverse cardiopulmonary outcomes, underscoring the need for earlier, aggressive therapeutic strategies.
